Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03558087 · ClinicalTrials.gov registry record · Phase 2
Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing
A Phase 2 study, sponsored by Matthew Galsky.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT03558087 is a Phase 2 study that has completed, run by Matthew Galsky. The registered enrollment target is 76 participants.
The verdict
NCT03558087, a Phase 2 study, has completed, sponsored by Matthew Galsky.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.
Interventions
- DRUG Cisplatin
- DRUG Nivolumab
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2018-07-13 |
| Est. Completion | 2024-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03558087
The ClinicalTrials.gov registry entry for NCT03558087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Matthew Galsky, which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cisplatin is the first listed.
NCT03558087 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03558087 about?
NCT03558087 is a clinical study titled "Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing". This is a phase 2 trial seeking to define the safety and activity of gemcitabine, cisplatin, plus nivolumab as neoadjuvant therapy in patients with muscle-invasive bladder cancer and to define the role of clinical complete response in predicting benefit in patients opting to avoid cystectomy.
What is the current status of trial NCT03558087?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2018-07-13. Estimated completion is 2024-03-07.
What interventions are being tested in trial NCT03558087?
The interventions under investigation include: Cisplatin (DRUG), Nivolumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03558087?
This trial is sponsored by Matthew Galsky, which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.